260
Trials as lead sponsor
Most active programmes
The drugs appearing most often across CSL's recently active trials. Comparator arms are excluded.
- CSL3126 trials
- Patiromer5 trials
- IgPro203 trials
- CSL3002 trials
- IgPro102 trials
- AAV5-hFIX2 trials
Upcoming readouts
Next primary completion dates among CSL's active phase 2 and phase 3 trials. Dates are registry estimates and move often, which is exactly what the tracker watches.
- Nov 2026Efficacy and Safety of 4F-PCC (4-Factor Prothrombin Complex Concentrate) in Adult Patients Under…Phase 3
- Sept 2027Phase 3 Study of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergo…Phase 3
- Oct 2027Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Dise…Phase 2
- Feb 2028Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults With Non-cystic Fib…Phase 2
- Mar 2028Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HF…Phase 2
- Jun 2028Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)Phase 2
Top therapeutic areas
Conditions studied most often across CSL's recently active trials.
- Influenza, Human12 trials
- Hemophilia B10 trials
- Hyperkalemia5 trials
- Hereditary Angioedema4 trials
- Virus Diseases4 trials
- Influenza4 trials
CSL trials
The 50 most significant of CSL's recently active trials, soonest estimated readout first.
Select any row for the full record; the change timeline unlocks with tracking.
| Trial | Phase | Stability | Status | Enrollment | Est. readout |
|---|---|---|---|---|---|
| Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII ProductsNCT06738485Recombinant single-chain factor VIII (rVIII-SingleChain) | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 60 est. | 26 Oct 2026 |
| Efficacy and Safety of 4F-PCC (4-Factor Prothrombin Complex Concentrate) in Adult Patients Undergoing Complex Cardiovascular Surgery With Cardiopulmonary Bypass (CPB)NCT07094087BE1116 | Phase 3 | Locked · track to reveal | OngoingRecruiting | 200 est. | 18 Nov 2026 |
| Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Chinese Subjects With Hemophilia B Previously Treated With FIX TherapyNCT06399289Recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 23 est. | 1 Dec 2026 |
| A Phase 1b Study to Evaluate the PK of CSL300 (Clazakizumab) in Chinese Subjects With End Stage Kidney Disease (ESKD)NCT07619820CSL300 | Phase 1 | Not yet scored | OngoingRecruiting | 24 est. | 30 Aug 2027 |
| Phase 3 Study of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreductive SurgeryNCT06617897CSL511 Fibrinogen concentrate (human) | Phase 3 | Locked · track to reveal | OngoingRecruiting | 90 est. | 1 Sept 2027 |
| Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive CrisisNCT06699849CSL889 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 70 est. | 22 Oct 2027 |
| pHeNIxHizentra® in Inflammatory Neuropathies - pHeNIx StudyNCT04672733Hizentra | — | Not yet scored | OngoingRecruiting | 100 est. | Dec 2027 |
| OrPHEeObservatory of Patients With Haemophilia B Treated by IdElvion®NCT05086575 | — | Not yet scored | OngoingActive, not recruiting | 222 est. | Dec 2027 |
| Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults With Non-cystic Fibrosis Bronchiectasis (NCFB)NCT07048262CSL787 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 450 est. | 28 Feb 2028 |
| Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary HemochromatosisNCT07332091Vamifeport | Phase 2 | Locked · track to reveal | OngoingRecruiting | 84 est. | 6 Mar 2028 |
| Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)NCT07224360Anumigilimab | Phase 2 | Locked · track to reveal | OngoingRecruiting | 63 est. | 29 Jun 2028 |
| GREATA Study Investigating the Effectiveness and Safety of Garadacimab for Treating Patients With Hereditary Angioedema (HAE)NCT07001280 | — | Not yet scored | OngoingRecruiting | 200 est. | 31 Aug 2028 |
| Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)NCT06003387CSL222 (AAV5-hFIXco-Padua) | Phase 3 | Locked · track to reveal | OngoingRecruiting | 35 est. | 4 Oct 2028 |
| Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting TherapiesNCT07648264IgPro20 | Phase 3 | Not yet scored | OngoingNot yet recruiting | 63 est. | 16 Feb 2029 |
| POSIBIL6ESKDCombined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)NCT05485961CSL300 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 3,110 est. | 22 May 2029 |
| Safety and Tolerability of Difelikefalin in Adolescents on Haemodialysis With Moderate-to-Severe PruritusNCT06593392Difelikefalin | Phase 2 | Locked · track to reveal | OngoingRecruiting | 18 est. | 15 Aug 2029 |
| Patiromer for Treatment of Hyperkalaemia in Children Under 12 Years of AgeNCT05766839Patiromer | Phase 2 | Locked · track to reveal | OngoingRecruiting | 32 est. | 1 Dec 2029 |
| Two Dose Levels of Privigen in Pediatric CIDPNCT03684018IgPro10 | Phase 4 | Locked · track to reveal | OngoingRecruiting | 30 est. | 20 Dec 2029 |
| AvacostarAvacostar - (PASS)NCT05897684 | — | Not yet scored | OngoingRecruiting | 500 est. | 1 Dec 2030 |
| Phase 4, Double-blind Study Evaluating the Response on Computed Tomography (CT) Lung Density Decline Rates of Respreeza / Zemaira Weekly for 3 Years in Adults With alpha1 Antitrypsin Deficiency (AATD)NCT07326592CE1226 | Phase 4 | Locked · track to reveal | OngoingNot yet recruiting | 270 est. | 15 Sept 2033 |
| IX-TEND 3004Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia BNCT07080905CSL222 (Adeno-associated viral vector serotype 5 [AAV5]-hFIXco-Padua) | Phase 3 | Locked · track to reveal | OngoingRecruiting | 20 est. | 24 Oct 2033 |
| IX-TEND 3003Long-term Follow-up Study of Male Adults With Hemophilia B Previously Treated With Etranacogene Dezaparvovec (CSL222)NCT05962398AAV5-hFIXco-Padua | — | Not yet scored | OngoingEnrolling by invitation | 56 est. | 23 Mar 2035 |
| IX-TEND 4001An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia BNCT06008938HEMGENIX | — | Not yet scored | OngoingRecruiting | 500 est. | 1 Aug 2043 |
| An Open-label, Multicenter Study to Assess the Pharmacokinetics (PK), Safety, and Tolerability of Subcutaneous IgPro20 in Immunoglobulin (IG) Treatment-naïve Participants With Primary Immunodeficiency (PID)NCT07076446IgPro | Phase 4 | Locked · track to reveal | Completed | 8 est. | 30 Jun 2026 |
| Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to GaradacimabNCT06806657Garadacimab | Phase 4 | Locked · track to reveal | OngoingActive, not recruiting | 18 est. | 23 Jun 2026 |
| A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of AgeNCT06087640aQIV or aTIV | Phase 3 | Locked · track to reveal | Completed | 38,769 est. | 26 May 2026 |
| Study of AAV5-hFIX in Severe or Moderately Severe Haemophilia BNCT05360706AAV5-hFIX | — | Not yet scored | Completed | 9 est. | 26 Mar 2026 |
| MODULAATEThe Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell TransplantNCT03805789AAT | Phase 2 | Locked · track to reveal | Completed | 222 est. | 19 Mar 2026 |
| First-In-Human Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Escalating Single And Multiple Doses Of CSL040 In Healthy SubjectsNCT05937581CSL040 | Phase 1 | Locked · track to reveal | Completed | 62 est. | 4 Dec 2025 |
| Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema AttacksNCT04739059CSL312 | Phase 3 | Locked · track to reveal | Completed | 171 est. | 21 Nov 2025 |
| CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary AngioedemaNCT05819775CSL312 | Phase 3 | Locked · track to reveal | Completed | 22 est. | 19 Nov 2025 |
| Patiromer JADETrial Evaluating the Efficacy and Safety of Patiromer in Chinese SubjectsNCT05136664Patiromer Powder for Oral Suspension (Part A) | Phase 3 | Locked · track to reveal | Completed | 262 est. | 18 Nov 2025 |
| Effect of Food on the Oral Bioavailability of a Prolonged-release Formulation of Vamifeport in Healthy AdultsNCT06996184Vamifeport (PR formulation) | Phase 1 | Locked · track to reveal | Completed | 28 est. | 1 Jul 2025 |
| Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTSNCT06524739IgPro20 | Phase 3 | Locked · track to reveal | StoppedTerminated | 16 est. | 20 Jun 2025 |
| Pharmacokinetics and Pharmacodynamics of Two Prolonged-release Formulations of Vamifeport in Healthy AdultsNCT06726863Vamifeport IRF | Phase 1 | Locked · track to reveal | Completed | 22 est. | 27 Jan 2025 |
| OPERARegister of Patients With haEmophilia A tReated With Afstyla®NCT04675541Afstyla® | — | Not yet scored | Completed | 62 est. | 31 Dec 2024 |
| RECLAIIMA Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM)NCT04044690human immunoglobulin G | Phase 3 | Locked · track to reveal | StoppedTerminated | 134 est. | 2 Dec 2024 |
| Study to Evaluate Immunogenicity, Safety and Tolerability of Adjuvanted and Non-Adjuvanted H2N3 Influenza Vaccines in AdultsNCT05875961Low dose A/H2N3c + standard dose MF59 | Phase 1 | Locked · track to reveal | Completed | 600 est. | 15 Nov 2024 |
| Evaluation of BE1116 in Patients With Traumatic Injury and Acute Major Bleeding to Improve Survival ( TAP Study )NCT05568888BE1116 | Phase 3 | Locked · track to reveal | StoppedTerminated | 1,366 est. | 29 Oct 2024 |
| Safety, Reactogenicity, and Immunogenicity Study of a Self-Amplifying MRNA Influenza Vaccine in Healthy AdultsNCT06028347sa-mRNA vaccine Dose 1 | Phase 1 | Locked · track to reveal | Completed | 96 est. | 13 Oct 2024 |
| Phase 3 Study of Difelikefalin in Haemodialysis Chinese Adult Subjects With Moderate-to-Severe PruritusNCT05885737Difelikefalin Injection | Phase 3 | Locked · track to reveal | Completed | 260 est. | 25 Sept 2024 |
| AmAREtTIRespreeza® Self-administration and Learning Program (AmAREtTI Study)NCT04262284 | — | Not yet scored | Completed | 15 est. | 6 May 2024 |
| Study to Evaluate Safety and Immunogenicity of Different Priming and Booster Regimens With Adjuvanted H5N8 and/or H5N6 Influenza Vaccine in AdultsNCT05874713aH5N8c on Day 1 | Phase 2 | Locked · track to reveal | Completed | 480 est. | 25 Apr 2024 |
| IMAGINEClazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant RecipientsNCT03744910Clazakizumab | Phase 3 | Locked · track to reveal | StoppedTerminated | 194 est. | 8 Apr 2024 |
| ViSionSerenityStudy to Assess Efficacy and Safety of VIT-2763 (Vamifeport) in Subjects With Sickle Cell DiseaseNCT04817670VIT-2763 120 mg | Phase 2 | Locked · track to reveal | Completed | 25 est. | 7 Mar 2024 |
| The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and OlderNCT06015282Investigational aQIVc | Phase 3 | Locked · track to reveal | Completed | 7,741 est. | 5 Mar 2024 |
| CARE-HKCardiovascular and Renal Treatment in Heart Failure Patients With Hyperkalaemia or at High Risk of HyperkalaemiaNCT04864795 | — | Not yet scored | Completed | 2,636 est. | 29 Feb 2024 |
| PORTRAYRAYALDEE Non Interventional Study (NIS) on Effectiveness in ND-CKD SHPT PatientsNCT05460234 | — | Not yet scored | Completed | 110 est. | 31 Jan 2024 |
| ReliefCensusCross-sectional Study to Assess Prevalence and Burden of CKD-associated Pruritus in Haemodialysis PatientsNCT05524467 | — | Not yet scored | Completed | 3,100 est. | 31 Jan 2024 |
| Garadacimab Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary FibrosisNCT05130970Garadacimab | Phase 2 | Locked · track to reveal | Completed | 81 est. | 2 Jan 2024 |